Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients

Penyige, Márton, Soltész, Szilágyi-Bónizs, Póka, Lukács, Széles, Nagy (2019) Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients Int J Mol Sci (IF: 5.6) 20(18)
Full Text
Full text

Click the PDF icon to view the full text of the paper

Abstract

Ovarian cancer is one of the most common cancer types in women characterized by a high mortality rate due to lack of early diagnosis. Circulating miRNAs besides being important regulators of cancer development could be potential biomarkers to aid diagnosis. We performed the circulating miRNA expression analysis in plasma samples obtained from ovarian cancer patients stratified into FIGO I, FIGO III, and FIGO IV stages and from healthy females using the NanoString quantitative assay. Forty-five miRNAs were differentially expressed, out of these 17 miRNAs showed significantly different expression between controls and patients, 28 were expressed only in patients, among them 19 were expressed only in FIGO I patients. Differentially expressed miRNAs were ranked by the network-based analysis to assess their importance. Target genes of the differentially expressed miRNAs were identified then functional annotation of the target genes by the GO and KEGG-based enrichment analysis was carried out. A general and an ovary-specific protein-protein interaction network was constructed from target genes. Results of our network and the functional enrichment analysis suggest that besides HSP90AA1, MYC, SP1, BRCA1, RB1, CFTR, STAT3, E2F1, ERBB2, EZH2, and MET genes, additional genes which are enriched in cell cycle regulation, FOXO, TP53, PI-3AKT, AMPK, TGFβ, ERBB signaling pathways and in the regulation of gene expression, proliferation, cellular response to hypoxia, and negative regulation of the apoptotic process, the GO terms have central importance in ovarian cancer development. The aberrantly expressed miRNAs might be considered as potential biomarkers for the diagnosis of ovarian cancer after validation of these results in a larger cohort of ovarian cancer patients.

Links

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769773
http://www.ncbi.nlm.nih.gov/pubmed/31540229
http://dx.doi.org/10.3390/ijms20184533

Similar articles

Tools